• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Sunday, February 5, 2023
SLC Metro News
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

Drugmakers Aim Big Price Hikes At U.S. Patients, Congressional Report Finds – Reuters

drugmakers-aim-big-price-hikes-at-us.-patients,-congressional-report-finds-–-reuters
Share on FacebookShare on Twitter

A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo

Register now for FREE unlimited access to reuters.com

WASHINGTON, Dec 10 (Reuters) – Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co (LLY.N), Novo Nordisk (NOVOb.CO) and Sanofi (SASY.PA), which dominate the market for insulin.

The staff report also noted pricing and marketing tactics by Pfizer Inc (PFE.N) that helped it earn billions of dollars from its now off-patent pain drug Lyrica.

The report, put out following a nearly three-year probe, took issue with assertions by the pharmaceutical industry that high drug prices were needed to fund innovation and research and development programs.

Register now for FREE unlimited access to reuters.com

“The Committee’s investigation also found that companies dedicated a significant portion of their R&D expenditures to research that was intended to extend market monopolies, support the companies’ marketing strategies, and suppress competition,” the report said.

The report, which focused on 12 drugs made by 10 companies, said that Lilly, Novo Nordisk and Sanofi own some 90% of the market for life-sustaining insulin, which was invented in the 1920s.

A Lilly spokesperson said the company offers discounts to make its insulin affordable. A Sanofi spokesperson said the price of its insulin product Lantus had declined almost 45% since 2012. A Novo Nordisk spokesperson said the report reflected a limited picture of the company’s efforts to make drugs accessible.

Medicare, the U.S. government health insurance program for those age 65 and older and the disabled, could have saved more than $16.7 billion from 2011 to 2017 on insulin purchases had it been allowed to negotiate discounts with drug companies, the report found.

“We found that drug companies target American patients for price increases, in large part because Medicare is prohibited from negotiating for lower prices. At the same time, the drug companies maintained or cut prices for the rest of the world,” Committee Chairwoman Carolyn Maloney said at a news conference on Friday.

The high prices have had human costs. More than 40% of insulin-dependent patients surveyed said they rationed their medicine in the previous year, the Colorado attorney general’s office found in a 2020 report.

PRODUCT HOPPING

President Joe Biden’s Build Back Better plan, which passed the House and should come before the Senate this year, includes a provision allowing Medicare to negotiate with drugmakers, although only for a small number of medicines. read more

The report also found that some pharmaceutical companies engage in what it called “product hopping,” a practice of making small tweaks to formulations to get a new patent and then switching patients to the newer, more expensive version. There are bills before Congress to ban product hopping. read more

Among big-selling insulin products, Eli Lilly raised the price of its Humalog 1,219% per vial since it launched, Novo Nordisk raised the price of NovoLog 627% since launch and Sanofi has raised the price of Lantus 715%, the report found.

The report also found that Pfizer targeted the U.S. market for higher prices for its blockbuster Lyrica, as well as using product hopping to prevent patients from shifting to cheaper, generic versions of the medicine.

Lyrica’s price had gone up 420% since it was approved in 2004, the report said. It had sales of about $2 billion in 2019.

Pfizer did not have an immediate comment.

The report also listed price hikes of 825% for Teva Pharmaceutical Industries’ (TEVA.TA) Copaxone, 486% for Amgen’s (AMGN.O) Enbrel, 395% for Novartis’ (NOVN.S) decades-old Gleevec, more than 100,000% for Mallinckrodt’s Acthar, 471% for AbbVie’s (ABBV.N) Humira and 82% for its Imbruvica, and 255% for Celgene’s Revlimid, now owned by Bristol Myers Squibb (BMY.N).

Most of the drugs mentioned in the report are over a decade old.

Novartis said it invested over 18% of its global revenue into R&D. Mallinckrodt and Bristol Myers did not have an immediate comment. Amgen, AbbVie, and Teva did not respond to requests for comment.

Register now for FREE unlimited access to reuters.com

Reporting by Diane Bartz; Additional Reporting by Ahmed Aboulenein in Washington; Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

SLC Metro News

© 2021 SLC Metro News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 SLC Metro News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT